Medivir AB (LTS:0GP7) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GP7 Medivir AB LTS:0GP7
59 GF Score
Price kr1.72
GF Value kr1.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB  (LTS:0GP7) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medivir AB Cyclically Adjusted PB Ratio Related Terms


Medivir AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted PB Ratio Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.30 0.16 0.15 0.04

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.03 0.22 0.19

LTS:0GP7 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


LTS:0GP7
59GF Score
Medivir AB LTS:0GP7
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.479/134.6100*134.6100
=0.479

Current CPI (Jun. 2026) = 134.6100.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 32.957 101.138 43.864
201612 43.309 102.022 57.143
201703 26.189 102.022 34.554
201706 23.145 102.752 30.321
201709 20.442 103.279 26.643
201712 17.030 103.793 22.086
201803 16.239 103.962 21.026
201806 13.677 104.875 17.555
201809 11.697 105.679 14.899
201812 8.524 105.912 10.834
201903 6.975 105.886 8.867
201906 6.637 106.742 8.370
201909 5.999 107.214 7.532
201912 5.113 107.766 6.387
202003 4.467 106.563 5.643
202006 4.109 107.498 5.145
202009 4.240 107.635 5.303
202012 3.932 108.296 4.887
202103 4.925 108.360 6.118
202106 4.671 108.928 5.772
202109 4.483 110.338 5.469
202112 4.133 112.486 4.946
202203 3.652 114.825 4.281
202206 3.312 118.384 3.766
202209 3.095 122.296 3.407
202212 2.834 126.365 3.019
202303 2.556 127.042 2.708
202306 2.137 129.407 2.223
202309 1.799 130.224 1.860
202312 2.086 131.912 2.129
202403 1.873 132.205 1.907
202406 1.536 132.716 1.558
202409 1.264 132.304 1.286
202412 1.030 132.987 1.043
202503 0.915 132.825 0.927
202506 0.710 133.699 0.715
202509 0.583 133.480 0.588
202512 0.346 133.380 0.349
202603 0.355 133.550 0.358
202606 0.479 134.610 0.479

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medivir AB (LTS:0GP7) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.72 is trading 38.5% above its estimated GF Value™ of kr1.24. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for LTS:0GP7:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr1.24 vs. price of kr1.72 (38.5% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
59GF Score

Get the complete analysis for LTS:0GP7

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.72
Price
kr1.24
GF Value